. PRISMA checklist for this meta-analysis.
Records identified through
database searching (n = 2026)
Screening

Included Eligibility Identification
Additional records identified through other sources (n = 1)
Records after duplicates removed (n = 1197)
Records screened (n = 1197)
Records excluded (n = 1171)
Full-text articles assessed for eligibility (n = 26)
Full-text articles excluded, with reasons (n = 20) Doubled cohort (n=3) No survival data (n=13) Reviews (n=2) No control group (n=2) Studies included in quantitative synthesis (meta-analysis) (n = 6) Voorneveld, 2013 * * * * ** * * * 9 Original studies were analyzed in the quality assessment.
* A study could be awarded a maximum of one star for each item except for the item Control for important factor or additional factor. The definition/explanation of each column of the Newcastle-Ottawa Scale is available at http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm. † For this index, one star was given if in Method section the SMAD2 expression was assessed with immunohistochemistry (IHC), or with whole section-IHC, or, in case of the use of tissue microarray-IHC, using at least 2 cores per case. † † Being outcome of interest mortality, we took as outcome of interest for assessment of quality if the overall survival or the recurrence rate was assessed. † † † A maximum of 2 stars could be awarded for this item. Studies that controlled their survival analyses for at least two confounders received one star, whereas studies that assessed and described the expression of also SMAD3, an additional star. † † † † A cohort study with a mean/median follow-up time ≥5 y (60 months) takes one star. Abbreviations: CRT: chemo-radiotherapy; G: histologic grading; GI: gastrointestinal; M: distant metastasis; pN: lymph node status in pathologic TNM; pT: tumor stage in pathologic TNM; R: radicalness of resection; TNM: tumor-node-metastasis staging system; TNM-S: TNM Stage.
